H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Roivant Sciences to $18 from $15 and keeps a Buy rating on the shares. Roivant recorded $13.7M in net product revenue for Vtama, surpassing the consensus of $12.1M, the analyst tells investors in a research note. The firm continues to see prescription volume maintaining an upward trajectory, with over 170,000 scripts written by approximately 11,000 unique prescribers since launch.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ROIV:
- UPDATE — Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
- Roivant Sciences expects cash to fund operations into 2H25
- Roivant Sciences announces upcoming milestones
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
- Roivant Sciences reports Q4 EPS from cont. ops. (20c), consensus (36c)